CollPlant Biotechnologies (NASDAQ:CLGN) reported quarterly losses of $(1.69) per share which missed the analyst consensus estimate of $(0.24) by 604.17 percent. This is a 26.52 percent increase over losses of $(2.30) per share from the same period last year. The company reported quarterly sales of $108.000 thousand which missed the analyst consensus estimate of $1.466 million by 92.63 percent. This is a 39.66 percent decrease over sales of $179.000 thousand the same period last year.